SanReno
THERAPEUTIC AREA
Renal
YEAR INVESTED
2021
STAGE
Private; acquired by Novartis in 2024
WEBSITE
Sanreno is a biotech company dedicated to developing therapies for kidney diseases and related conditions. With a focus on research, development, and commercialization, Sanreno aims to bring innovative treatments to market that enhance the quality of life for patients affected by kidney-related health issues.
